ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ウルソデオキシコール酸

Ursodeoxycholic Acid

HCID 31401
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
128-13-2
標準SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
分子式
C24H40O4
平均分子量
392.6 g/mol
単同位体質量
392.29265975

概要

Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a mouse metabolite and a human metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of an ursodeoxycholate.

名称と識別子

優先名称
Ursodeoxycholic Acid
IUPAC
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
現地名
ウルソデオキシコール酸
英語名
Ursodeoxycholic acid
分子式
C24H40O4
分子量
392.57

名称と別名

URSODEOXYCHOLIC ACIDursodiol128-13-2UDCAActigallUrsodesoxycholic acidUrso ForteDeursil3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acidAcido ursodeoxicolicoUrso 250Ursonorm
名称をさらに表示
ウルソデオキシコール酸ウルサミックプレコートデオキシウルソコール酸ウルサコールオキシコールウルソジオールウルデナシン3α,7β-ジヒドロキシ-5β-コラン-24-酸3α,7β-ジヒドロキシ-5β-コラン酸コリット-ウルサンウルソゴクミシンウビロンデルウルサンウルソデソキシコール酸ウルソデスオキシコール酸デウルシルデストリットウルソコールUrsodeoxycholicURSODEOXYCHOLATETauroursodiol3-alpha,7-beta-dihydroxy-5-beta-cholanoicacidUrosodeoxycholic AcidPorcine deoxycholic acidurso
Acidum ursodeoxycholicum(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acidacide ursodeoxycholiqueDTXSID6023731724L30Y2QRDeoxyursocholic AcidNSC-683769

物性

構造計算による物性

XLogP
4.9
極性表面積
77.8 Ų
水素結合供与体数
3
水素結合受容体数
4
回転可能結合数
4
重原子数
28
形式電荷
0
複雑度
605

実験および物理化学的性質

Chemical ClassesBile Acids -> Quant Bile Acids
Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LipidsLipids -> Sterol Lipids [ST] -> Bile acids and derivatives [ST04] -> C24 bile acids, alcohols, and derivatives [ST0401]
LogP3.00
Solubility0.02 mg/mL
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Bile Acids and Salts; Cholagogues and Choleretics; Cholic Acids; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 件

200-205

203 °C

Physical DescriptionSolid
Collision Cross Section · 5 件

200.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: Bile Acids]

208.98 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

198.7 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports.

Warning

H315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

REACH registered substance: Ursodeoxycholic acid (EC: 204-879-3)

Ursodeoxycholic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (95.5%)

毒性情報

Hepatotoxicity · 1 件

n multiple clinical trials in a variety of conditions, ursodiol has not been found to cause increases in serum enzyme elevations, worsening of underlying liver disease or clinically apparent liver injury. Nevertheless, there have been rare reports of clinical decompensation in patients with advanced liver disease and cirrhosis started on ursodiol, but the reason for such reactions is not known. In at least one instance, there was recurrence of jaundice on restarting ursodiol. Thus, ursodiol has beneficial effects on several forms of liver disease and has not been convincingly linked to cases of clinically apparent acute liver injury in patients without cirrhosis. There is some concern that ursodiol may be harmful in patients with advanced liver disease (Childs class B and C) and such patients probably should not receive ursodiol.

化学と産業

薬理情報

ATC Code · 3 件

A05AA02

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingUnconjugated ursodeoxycholic acid is at least 70% bound to plasma proteins in health individuals. There is no information regarding the protein binding of conjugated ursodeoxycholic acid.
Pharmacodynamics · 1 件

Ursodeoxycholic acid (UDCA) is a secondary bile acid with cytoprotectant, immunomodulating, and choleretic effects. It reduces the cholesterol fraction of biliary lipids. UDCA inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation. UDCA increases bile acid flow and promotes the secretion of bile acids.

Mechanism of Action · 1 件

Endogenous hydrophobic bile acids such as deoxycholic acid and chenodeoxycholic acid can exert hepatotoxic effects. Ursodeoxycholic acid is a hydrophilic bile acid that mediates its biological effects via several mechanisms. Ursodeoxycholic acid (UDCA) protects hepatocytes and cholangiocytes from bile acid-induced damage, such as reactive oxygen species (ROS)-induced inflammation and mitochondrial dysfunction. UDCA was shown to reserve hepatocyte cell structures and stimulate anti-apoptotic pathways. It was also shown to prevent the production of ROS by Kupffer cells and resident macrophages in the liver, thus attenuating oxidative stress in the liver. UDCA can also change the hydrophobicity index of the bile acid pool: following oral administration, UDCA forms a major fraction of the human bile acid pool and competitively displaces the hydrophobic or more toxic bile acids. It increases the absorption of hydrophilic bile acids. There are several proposed mechanisms of choleretic actions of UDCA: UDCA increases intracellular calcium levels, stimulating transport proteins and vesicular exocytosis in cholestatic hepatocytes. UDCA may also upregulate the expression of membrane transport proteins like the chloride-bicarbonate anion exchanger (AE2), which is involved in biliary secretion and is often observed to be defective in primary biliary cholangitis. In rats, UDCA reduced hepatic expression of major histocompatibility complex (MHC) class I antigens, suggesting immunomodulating effects. UDCA acts as a partial agonist at the bile acid receptor, also known as the farnesoid X receptor (FXR), and has negligible effects on cholesterol and lipid synthesis.

関連反応

7 件
反応記録を作成
HRID 464235 の反応式
HRID 464235生成物として
HRID 865406 の反応式
HRID 865406反応物として
HRID 893896 の反応式
HRID 893896生成物として
HRID 1153703 の反応式
HRID 1153703生成物として
HRID 1659375 の反応式
HRID 1659375生成物として
HRID 1721147 の反応式
HRID 1721147反応物として
HRID 2371860 の反応式
HRID 2371860反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
128-13-2
PubChem CID
31401
DTXSID
DTXSID6023731
ChEMBL
CHEMBL1551
ChEBI
CHEBI:9907
UNII
724L30Y2QR
EC Number
204-879-3
Nikkaji
J2.520H

186.8 Ų [M+H-2H2O]+ [CCS Type: DT; Method: single field calibrated]

198.86 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
203 · 203-204 °C (lit.)
比旋光度
60 · 60 º (c=2, EtOH)
沸点
437.26 °C · 437.26°C (rough estimate)
比重(密度)
0.9985 · 0.9985 (rough estimate)
屈折率
60.5 ° · 60.5 ° (C=2, EtOH)
闪点
9 ℃ · 9℃
貯蔵温度
2 · 2-8°C
溶解性
50 mg/mL、透明 · エタノール: 50 mg/mL、透明
外見
個体。粉。
酸解離定数(Pka)
5.04 · pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
色
白 - ほぼ白。
水溶解度
実質的に不溶
Merck
14 · 14,9889
BRN
3219888 · 3219888
化粧品成分の機能
スキンコンディショニング - その他肌を保護する
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LogP
3 · 3-3.38 at 20℃
CAS データベース
128 · 128-13-2(CAS DataBase Reference)

化学的性質

化学的特性WHITE CRYSTALLINE POWDER

Adverse Effects · 1 件

UDCA is a mostly well-tolerated drug. In most clinical trials, diarrhea was the most frequent adverse event observed during UDCA treatment in patients with gallstone disease, with a reported incidence of 2 to 9%. The mechanism behind this side effect is unclear. However, researchers have proposed that bacterial conversion of UDCA to chenodeoxycholic acid, which serves as a potent secretory substance, could significantly contribute to this side effect. In patients with primary biliary cirrhosis, right upper quadrant abdominal pain was the most commonly reported side effect. Reports also exist of skin reactions in those with primary biliary cirrhosis. The most common dermatological manifestation was an exacerbation of pruritus, even though UDCA has demonstrated effectiveness in relieving pruritus in patients with PBC in other trials.

Toxicity Summary · 1 件

UDCA has been shown to have potentially toxic molecular properties. UDCA breaks down into toxic lithocholic acid. After being absorbed in the small intestine, UDCA undergoes hepatic conjugation. Beyond conjugation, UDCA does not experience further breakdown by the liver or intestinal mucosa. It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to liver cells and even cause liver failure in those with compromised sulfation. It also leads to segmental bile duct injury, hepatocyte failure, and death.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ursodiol

Ambiguous-DILI-concern

0

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

F
10
wgk
2
rtecs
FZ2000000
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
毒性
LD50 in mice (g/kg): 0.1 i.v. (Ardenne, Reitnauer); in rats, mice (mg/kg): 2000, 6000 s.c.; 1000, 1200 i.p., 310, 260 i.v. (Ward)
hs_code
29181990
risk_code
36/37/38
化審法
(9)-2157
hazard_code
Xi
safety_code
24/25-36-26
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2
ストレージクラス
11 - Combustible Solids
Biological Half-LifeThe estimated half-life ranges from 3.5 to 5.8 days.
Metabolism/Metabolites · 1 件

Upon administration, ursodeoxycholic acid (UDCA) enters the portal vein and into the liver, where it undergoes conjugation with glycine or taurine. UDCA is also decreased into bile. Glycine or taurine conjugates are absorbed in the small intestine via passive and active mechanisms. The conjugates can also be deconjugated in the ileum by intestinal enzymes, leading to the formation of free UDCA that can be reabsorbed and re-conjugated in the liver. Nonabsorbed UDCA passes into the colon, where it undergoes 7-dehydroxylation by intestinal bacteria to lithocholic acid. Some UDCA is epimerized to [chenodeoxycholic acid] via a 7-oxo intermediate. Chenodeoxycholic acid also undergoes 7-dehydroxylation to form lithocholic acid. These metabolites are poorly soluble and excreted in the feces. A small portion of lithocholic acid is reabsorbed, conjugated in the liver with glycine or taurine, and sulfated at the 3 position. The resulting sulfated lithocholic acid conjugates are excreted in bile and then lost in feces.

FDA Pharmacological Classification · 6 件

724L30Y2QR

URSODIOL

Established Pharmacologic Class [EPC] - Bile Acid

Chemical Structure [CS] - Bile Acids and Salts

Ursodiol is a Bile Acid.

URSODIOL

MeSH Pharmacological ClassificationGastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
Absorption, Distribution and Excretion · 3 件

Normally, endogenous ursodeoxycholic acid constitutes a minor fraction (about 5%) of the total human bile acid pool. Following oral administration, the majority of ursodiol is absorbed by passive diffusion, and its absorption is incomplete. Once absorbed, ursodiol undergoes hepatic extraction to about 50% in the absence of liver disease. As the severity of liver disease increases, the extent of extraction decreases. During chronic administration of ursodiol, it becomes a major biliary and plasma bile acid. At a chronic dose of 13 to 15 mg/kg/day, ursodiol constitutes 30-50% of biliary and plasma bile acids.

Ursodeoxycholic acid is excreted primarily in the feces. Renal elimination is a minor elimination pathway. With treatment, urinary excretion increases but remains less than 1% except in severe cholestatic liver disease.

The volume of distribution of ursodeoxycholic acid (UDCA) has not been determined; however, it is expected to be small since UDCA is mostly distributed in the bile in the gallbladder and small intestines.

Tissue LocationsAdrenal Cortex
Cellular LocationsExtracellular

用途と製造

UsesUse (kg; approx.) in Germany (2009): >10000
応用分野 · 5 件

解説ウルソデオキシコール酸,(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid.C24H40O4(392.57).コール酸より誘導される.白色の結晶または粉末.融点200~204 ℃.[α]20D+54~+60°(エタノール).エタノールに易溶,エーテルに難溶,水に不溶.ツキノワグマの肝汁中にタウリンとの抱合体として見いだされた.肝機能改善薬として,また,胆石溶解剤にも使用される.

用途胆汁分泌を促進する作用を示 します。

用途胆汁分泌を促進する作用を示 します。

使用Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. It is also used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.

一般的な説明Ursodeoxycholic acid (UDCA) is a secondary bile acid that helps regulate cholesterol. Mass spectrometry-based analysis of UDCA is routinely performed in clinical diagnostic testing applications such as neonatal testing of inborn errors of bile acid synthesis, differentiating among types of familial intrahepatic cholestasis, and therapeutic monitoring of patient responses to UDCA therapy. This Certified Spiking Solution is suitable as a starting material in preparation of linearity standards, calibrators, and controls for use in LC-MS/MS and GC/MS bile acid testing methods.

調製方法

純化方法Recrystallise ursodiol from wet Et2O, EtOH or EtOH/MeOH. [Iwasaki Hoppe Seyler's Z Physiol Chem 244 181, 183 1936, Beilstein 10 III 1635.]

上流・下流製品情報

上流原料

ジエチレングリコールジアセチルケノデオキシコール酸コール酸メチルクロム酸二カリウムメタノールAcetylcholic acid5α-コラン酸酢酸塩酸トリオキソクロム(VI)ナトリウム

下流製品

ノルウルソデオキシコール酸Ethyl Ursodeoxycholate2-[[(3α,5β,7β)-3,7-ジヒドロキシ-24-オキソコラン-24-イル]アミノ]エタンスルホン酸ナトリウム
補足説明 · 1 件

定義ChEBI: Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of an ursodeoxycholate.